Figure 2.

Memory CD8+ T cells primed by Lm-OVA infection in tacrolimus treated mice. (a) Percent lysis of OVA_257–264 pulsed compared with unpulsed control donor CD45.1 cells after intravenous transfer into tacrolimus treated compared with no treatment control mice each 30 days after primary Lm-OVA infection. (b) Representative FACS plots and composite data showing the percent OVA-specific CD8+ T cells identified by H-2K^b:OVA_257–264 tetramer staining and total number amongst splenocytes 30 days after primary Lm-OVA infection for tacrolimus treated compared with no treatment control mice. (c) Relative expression of each marker by H-2K^b:OVA_257–264 tetramer staining CD8+ T cells (blue or red) compared with tetramer negative CD8+ splenocytes 30 days after primary Lm-OVA infection for tacrolimus treated compared with no treatment control mice. (d) Relative intensity of H-2K^b:OVA_257–264 tetramer staining by OVA-specific CD8+ T cells and H-2K^b:OVA_257–264 avidity after normalization for levels of T cell receptor (CD3) expression amongst splenocytes 30 days after primary Lm-OVA infection for tacrolimus treated compared with no treatment control mice. (e) Cytokine production after OVA257–264 peptide stimulation compared with no stimulation controls by CD8+ splenocytes 30 days after primary Lm-OVA infection for tacrolimus treated compared with no treatment control mice. Data is from at least two independent experiments each with similar results, with each point representing data from an individual mouse. Bar, mean ± SEM.